Focal therapy of prostate cancer: Energies and procedures

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 2, 2013, Pages 155-167

  Bozzini, G ^a,b,c   Colin, P ^a,b,c   Nevoux, P ^a,b,c   Villers, A ^a,b,c   Mordon, S ^b,c   Betrouni, N ^b,c  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c UNIV LILLE   (France)

Author keywords

Cryotherapy; Focal laser ablation; Focal therapy; HIFU; Photodynamic therapy; Prostate cancer

Indexed keywords

PHOTOSENSITIZING AGENT;

CANCER THERAPY; CONSERVATIVE TREATMENT; CRYOTHERAPY; ELECTROPORATION; EXTERNAL BEAM RADIOTHERAPY; FOCAL LASER ABLATION; FOCAL THERAPY; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; LASER SURGERY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; RADIOFREQUENCY ABLATION; REVIEW;

CATHETER ABLATION; CRYOTHERAPY; ELECTROCHEMOTHERAPY; HUMANS; LASER THERAPY; MALE; PHOTOCHEMOTHERAPY; PROSTATIC NEOPLASMS; RADIOTHERAPY;

EID: 84875265104     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2012.05.011     Document Type: Review

References (87)

1. Umbehr M., Bachmann L.M., Held U., et al. Combined magnetic resonance imaging and magnetic resonance spectroscopy imaging in the diagnosis of prostate cancer: A systematic review and meta-analysis. Eur Urol 2009, 55:575-590.
2. Hu J.C., Gu X., Lipsitz S.R., et al. Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA 2009, 302:1557-1564.
3. Cahlon O., Hunt M., Zelefsky M.J. Intensity-modulated radiation therapy: Supportive data for prostate cancer. Semin Radiat Oncol 2008, 18:48-57.
4. Sharma N.L., Shah N.C., Neal D.E. Robotic-assisted laparoscopic prostatectomy. Br J Cancer 2009, 101:1491-1496.
5. Parker C., Muston D., Melia J., et al. A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer 2006, 94:1361-1368.
6. Schröder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009, 360:1320-1328.
7. Klotz L., Zhang L., Lam A., et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010, 28:126-131.
8. Bill-Axelson A., Holmberg L., Ruutu M., et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011, 364:1708-1717.
9. de la Rosette J., Ahmed H., Barentsz J., et al. Focal therapy in prostate cancer-report from a consensus panel. J Endourol 2010, 24:775-780.
10. Villers A., McNeal J.E., Freiha F.S., et al. Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors. Cancer 1992, 70:2313-2318.
11. Meiers I., Waters D.J., Bostwick D.G. Preoperative prediction of multifocal prostate cancer and application of focal therapy: Review 2007. Urology 2007, 70(6 Suppl):3-8.
12. Noguchi M., Stamey T.A., McNeal J.E., et al. Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: Lack of significance of secondary cancers. J Urol 2003, 170:459-463.
13. Stamey T.A., McNeal J.E., Yemoto C.M., et al. Biological determinants of cancer progression in men with prostate cancer. JAMA 1999, 281:1395-1400.
14. Bostwick D.G., Waters D.J., Farley E.R., et al. Group consensus reports from the Consensus Conference on Focal Treatment of Prostatic Carcinoma, Celebration, Florida, February 24, 2006. Urology 2007, 70(6 Suppl):42-44.
15. Mouraviev V., Villers A., Bostwick D.G., et al. Understanding the pathological features of focality, grade and tumor volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: Active surveillance and focal targeted therapy. BJU Int 2011, 108:1074-1085.
16. Onik G.M., Cohen J.K., Reyes G.D., et al. Transrectal ultrasound-guided percutaneous radical cryosurgical ablation of the prostate. Cancer 1993, 72:1291-1299.
17. Rees J., Patel B., MacDonagh R., et al. Cryosurgery for prostate cancer. BJU Int 2004, 93:710-714.
18. Abdelaziz S., Esteveny L., Renaud P., et al. Design considerations for a novel MRI compatible manipulator for prostate cryoablation. Int J Comput Assist Radiol Surg 2011, 6:811-819.
19. Caviezel A., Terraz S., Schmidlin F., et al. Percutaneous cryoablation of small kidney tumours under magnetic resonance imaging guidance: Medium-term follow-up. Scand J Urol Nephrol 2008, 42:412-416.
20. Bahn D.K., Silverman P., Lee F., et al. Focal prostate cryoablation: Initial results show cancer control and potency preservation. J Endourol 2006, 20:688-692.
21. Lambert E.H., Bolte K., Masson P., et al. Focal cryosurgery: Encouraging health outcomes for unifocal prostate cancer. Urology 2007, 69:1117-1120.
22. Ellis D.S., Manny T.B., Rewcastle J.C. Focal cryosurgery followed by penile rehabilitation as primary treatment for localized prostate cancer: Initial results. Urology 2007, 70(6 Suppl):9-15.
23. Dhar N, Cher ML, Scionti SM, et al. Focal = partial gland prostate cryoablation: Results of 795 patients from multiple centers tracked with the COLD registry. Abstracts of the American Urological Association (AUA) 104th Annual Scientific Meeting. April 25-30, 2009, Chicago, IL. [Abstract 1975].
24. Onik G., Vaughan D., Lotenfoe R., et al. The "male lumpectomy": Focal therapy for prostate cancer using cryoablation results in 48 patients with at least 2-year follow-up. Urol Oncol 2008, 26:500-505.
25. Onik G., Vaughan D., Lotenfoe R., et al. "Male lumpectomy": Focal therapy for prostate cancer using cryoablation. Urology 2007, 70(6 Suppl):16-21.
26. Truesdale M.D., Cheetham P.J., Hruby G.W., et al. An evaluation of patient selection criteria on predicting progression-free survival after primary focal unilateral nerve-sparing cryoablation for prostate cancer: Recommendations for follow up. Cancer J 2010, 16:544-549.
27. Beerlage H.P., van Leenders G.J., Oosterhof G.O., et al. High-intensity focused ultrasound (HIFU) followed after one to two weeks by radical retropubic prostatectomy: Results of a prospective study. Prostate 1999, 39:41-46.
28. Kennedy J.E., Ter Haar G.R., Cranston D. High intensity focused ultrasound: Surgery of the future?. Br J Radiol 2003, 76:590-599.
29. Ahmed H.U., Hindley R.G., Dickinson L., et al. Focal therapy for localized unifocal and multifocal prostate cancer: A prospective development study. Lancet Oncol 2012, 13:622-632.
30. Madersbacher S., Pedevilla M., Vingers L., et al. Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res 1995, 55:3346-3351.
31. Muto S., Yoshii T., Saito K., et al. Focal therapy with high-intensity-focused ultrasound in the treatment of localized prostate cancer. Jpn J Clin Oncol 2008, 38:192-199.
32. Ahmed H.U., Freeman A., Kirkham A., et al. Focal therapy for localized prostate cancer: A phase I/II trial. J Urol 2011, 185:1246-1254.
33. El Fegoun A.B., Barret E., Prapotnich D., et al. Focal therapy with high-intensity focused ultrasound for prostate cancer in the elderly. A feasibility study with 10 years follow-up. Int Braz J Urol; Official J Brazilian Society of Urology 2011, 37:213-222.
34. Crouzet S., Murat F.J., Pasticier G., et al. High intensity focused ultrasound (HIFU) for prostate cancer: Current clinical status, outcomes and future perspectives. Int J Hyperthermia 2010, 26:796-803.
35. Raab O. Über die Wirkung fluoreszierenden Stoffen. Infusoria Z Biol 1900, 39:524.
36. Tappeiner H., Jesionek A. Therapeutische Versuch mit fluoreszierender Stoff. Munchen Med Wehnschr 1903, 1:2,042-2,044.
37. Moore C.M., Pendse D., Emberton M. Photodynamic therapy for prostate cancer-a review of current status and future promise. Nat Clin Pract Urol 2009, 6:18-30.
38. Figge F.H., Weiland G.S., Manganiello L.O. Studies on cancer detection and therapy; the affinity of neoplastic, embryonic, and traumatized tissue for porphyrins, metalloporphyrins, and radioactive zinc hematoporphyrin. Anat Rec 1948, 101:657.
39. Pottier R., Kennedy J.C. The possible role of ionic species in selective biodistribution of photochemotherapeutic agents toward neoplastic tissue. J Photochem Photobiol B Biol 1990, 8:1-16.
40. Ficheux H. [Photodynamic therapy: Principles and therapeutic indications]. Ann Pharm Fr 2009, 67:32-40.
41. Dougherty T.J., Gomer C.J., Henderson B.W., et al. Photodynamic therapy. J Natl Cancer Inst 1998, 90:889-905.
42. Ascencio M., Collinet P., Farine M.O., et al. Protoporphyrin IX fluorescence photobleaching is a useful tool to predict the response of rat ovarian cancer following hexaminolevulinate photodynamic therapy. Lasers Surg Med 2008, 40:332-341.
43. Sultan S.M., El-Doray A.A., Hofstetter A., et al. Photodynamic selectivity of 5-aminolevulinic acid to prostate cancer cells. J Egypt Natl Cancer Inst 2006, 18:382-386.
44. Zaak D., Stroka R., Hoppner M., et al. Photodynamic therapy by means of 5 ALA induced protoporphyrin IX in human prostate cancer e preliminary results. Med Laser Appl 2003, 18:91-95.
45. Azzouzi A.-R., Emberton M. Results of Tookad soluble vascular targeted photodynamic therapy (VTP) for low risk localized prostate cancer (PCM203) 2011, AUA 2011, Washington, DC.
46. Arumainayagam N, Moore MC, Allen C, et al. Tookad soluble (padeliporfin) second generation vascular targeted photodynamic therapy (VTP) for prostate cancer: Safety and feasibility. EAU 2010, Barcelona: Annual Meeting.
47. Jankun J., Keck R.W., Skrzypczak-Jankun E., et al. Diverse optical characteristic of the prostate and light delivery system: Implications for computer modeling of prostatic photodynamic therapy. BJU Int 2005, 95:1237-1244.
48. Betrouni N., Lopes R., Puech P., et al. A model to estimate the outcome of prostate cancer photodynamic therapy with Tookad soluble WST11. Phys Med Biol 2011, 56:4771-4783.
49. Curnow A., MacRobert A.J., Bown S.G. Comparing and combining light dose fractionation and iron chelation to enhance experimental photodynamic therapy with aminolevulinic acid. Lasers Surg Med 2006, 38:325-331.
50. Xiao Z., Halls S., Dickey D., et al. Fractionated versus standard continuous light delivery in interstitial photodynamic therapy of dunning prostate carcinomas. Clin Cancer Res 2007, 13:7496-7505.
51. Fingar V.H., Wieman T.J., Park Y.J., et al. Implications of a pre-existing tumor hypoxic fraction on photodynamic therapy. J Surg Res 1992, 53:524-528.
52. Henderson B.W., Fingar V.H. Relationship of tumor hypoxia and response to photodynamic treatment in an experimental mouse tumor. Cancer Res 1987, 47:3110-3114.
53. Gonzalez S., Arnfield M.R., Meeker B.E., et al. Treatment of dunning R3327-AT rat prostate tumors with photodynamic therapy in combination with misonidazole. Cancer Res 1986, 46:2858-2862.
54. Bown S.G. Science, medicine, and the future. New techniques in laser therapy. BMJ 1998, 316:754-757.
55. Muschter R., Zellner M., Hessel S., et al. Interstitial laser coagulation of the prostate: Experiences in the treatment of benign prostatic hyperplasia. Prog Clin Biol Res 1994, 386:521-527.
56. Muschter R., de la Rosette J.J., Whitfield H., et al. Initial human clinical experience with diode laser interstitial treatment of benign prostatic hyperplasia. Urology 1996, 48:223-228.
57. McNicholas T.A., Steger A.C., Bown S.G. Interstitial laser coagulation of the prostate. An experimental study. Br J Urol 1993, 71:439-444.
58. Woodrum D.A., Gorny K.R., Mynderse L.A., et al. Feasibility of 3.0T magnetic resonance imaging-guided laser ablation of a cadaveric prostate. Urology 2010, 75:e1511-e1516.
59. McNichols R.J., Gowda A., Kangasniemi M., et al. Thermometry-based feedback control of laser interstitial thermal therapy at 980 nm. Lasers Surg Med 2004, 34:48-55.
60. Lindner U., Lawrentschuk N., Weersink R.A., et al. Focal laser ablation for prostate cancer followed by radical prostatectomy: Validation of focal therapy and imaging accuracy. Eur Urol 2010, 57:1111-1114.
61. Lindner U., Weersink R.A., Haider M.A., et al. Image guided photothermal focal therapy for localized prostate cancer: Phase I trial. J Urol 2009, 182:1371-1377.
62. Colin P., Nevoux P., Marqa M., et al. Focal laser interstitial thermotherapy (LITT) at 980 nm for prostate cancer: Treatment feasibility in dunning R3327-AT2 rat prostate tumor. BJU Int 2011, 109:452-458.
63. Sherar M.D., Gertner M.R., Yue C.K., et al. Interstitial microwave thermal therapy for prostate cancer: Method of treatment and results of a phase I/II trial. J Urol 2001, 166:1707-1714.
64. Lancaster C., Toi A., Trachtenberg J. Interstitial microwave thermoablation for localized prostate cancer. Urology 1999, 53:828-831.
65. Cheng H.L., Haider M.A., Dill-Macky M.J., et al. MRI and contrast-enhanced ultrasound monitoring of prostate microwave focal thermal therapy: An in vivo canine study. J Magn Reson Imaging 2008, 28:136-143.
66. Djavan B., Zlotta A.R., Susani M., et al. Transperineal radiofrequency interstitial tumor ablation of the prostate: Correlation of magnetic resonance imaging with histopathologic examination. Urology 1997, 50:986-992. Discussion: 992-83.
67. Zlotta A.R., Djavan B., Matos C., et al. Percutaneous transperineal radiofrequency ablation of prostate tumor: Safety, feasibility and pathological effects on human prostate cancer. Br J Urol 1998, 81:265-275.
68. Shariat S.F., Raptidis G., Masatoschi M., et al. Pilot study of radio frequency interstitial tumor ablation (RITA) for the treatment of radio-recurrent prostate cancer. Prostate 2005, 65:260-267.
69. Aluwini S., van Rooij P., Hoogeman M., et al. Cyberknife stereotactic radiotherapy as monotherapy for low- to intermediate-stage prostate cancer: Early experience, feasibility, and tolerance. J Endourol 2010, 24:865-869.
70. Budiharto T., Haustermans K., Kovacs G. External beam radiotherapy for prostate cancer. J Endourol 2010, 24:781-789.
71. Miralbell R., Mollà M., Rouzaud M., et al. Hypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: A sequential dose escalation pilot study. Int J Radiat Oncol Biol Phys 2010, 78:50-57.
72. Fonteyne V., Villeirs G., Speleers B., et al. Intensity-modulated radiotherapy as primary therapy for prostate cancer: Report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. Int J Radiat Oncol Biol Phys 2008, 72:799-807.
73. De Meerleer G., Villeirs G., Bral S., et al. The magnetic resonance detected intraprostatic lesion in prostate cancer: Planning and delivery of intensity-modulated radiotherapy. Radiother Oncol 2005, 75:325-333.
74. Gaudet M., Vigneault E., Aubin S., et al. Dose escalation to the dominant intraprostatic lesion defined by sextant biopsy in a permanent prostate I-125 implant: A prospective comparative toxicity analysis. Int J Radiat Oncol Biol Phys 2010, 77:153-159.
75. Singh A.K., Guion P., Sears-Crouse N., et al. Simultaneous integrated boost of biopsy proven, MRI defined dominant intra-prostatic lesions to 95 Gray with IMRT: Early results of a phase I NCI study. Radiot Oncol 2007, 2:36.
76. Lips I.M., van der Heide U.A., Haustermans K., et al. Single blind randomized phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): Study protocol for a randomized controlled trial. Trials 2011, 12:255.
77. Kagan A.R., Schulz R.J. Proton-beam therapy for prostate cancer. Cancer J 2010, 16:405-409.
78. Onik G., Mikus P., Rubinsky B. Irreversible electroporation: Implications for prostate ablation. Technol Cancer Res Treat 2007, 6:295-300.
79. Johannsen M., Thiesen B., Wust P., et al. Magnetic nanoparticle hyperthermia for prostate cancer. Int J Hyperthermia 2010, 26:790-795.
80. Heidenreich A., Aus G., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 2008, 53:68-80.
81. Taneja S.S., Mason M. Candidate selection for prostate cancer focal therapy. J Endourol 2010, 24:835-841.
82. Barzell W.E., Melamed M.R. Appropriate patient selection in the focal treatment of prostate cancer: The role of transperineal 3-dimensional pathologic mapping of the prostate-a 4-year experience. Urology 2007, 70(6 Suppl):27-35.
83. Onik G., Miessau M., Bostwick D.G. Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. J Clin Oncol 2009, 27:4321-4326.
84. Taira A.V., Merrick G.S., Galbreath R.W., et al. Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting. Prostate Cancer Prostatic Dis 2010, 13:71-77.
85. Villers A., Puech P., Mouton D., et al. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: Correlation with radical prostatectomy findings. J Urol 2006, 176:2432-2437.
86. Ukimura O., Hung A.J., Gill I.S. Innovations in prostate biopsy strategies for active surveillance and focal therapy. Curr Opin Urol 2011, 21:115-120.
87. Tsivian M., Polascik T.J. Focal cryotherapy for prostate cancer. Curr Urol Rep 2010, 11:147-151.